Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model.

Published

Journal Article

The combination of tumor necrosis factor (TNF) and etoposide (ETP) was evaluated for potential cytotoxic efficacy against a human renal cell carcinoma xenograft using an in vivo assay employing an athymic mouse host with tumor implanted a the subrenal capsule site. Both antitumor efficacy (relative survival or RTS) and toxicity (weight loss) of TNF and ETP alone and in combination were evaluated. While TNF and ETP alone were mildly inhibitory (RTS 90% and 71%, respectively), the combination caused marked tumor inhibition (45% of controls). Host toxicity encountered with the combination did not exceed the toxicity associated with ETP alone, suggesting that the therapeutic index may have been augmented. It is concluded that enhanced antitumor activity without substantial augmentation of toxicity is observed with this combination, providing a rationale for further evaluation of tumor necrosis factor-based regimens for the treatment of advanced renal carcinoma.

Full Text

Duke Authors

Cited Authors

  • Donaldson, JT; Keane, TE; Poulton, SH; Walther, PJ

Published Date

  • 1990

Published In

Volume / Issue

  • 18 / 4

Start / End Page

  • 245 - 250

PubMed ID

  • 2219586

Pubmed Central ID

  • 2219586

International Standard Serial Number (ISSN)

  • 0300-5623

Digital Object Identifier (DOI)

  • 10.1007/bf00294766

Language

  • eng

Conference Location

  • Germany